A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Active, not recruiting · Phase 3 · NCT06425549
Conditions: Moderate to Severe Plaque Psoriasis
At a glance
- Research payments reported, 2025
- $281,120
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 176
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- bimekizumab (drug), ustekinumab (drug), placebo (drug)
- Dates
- Started 2024-06-25; completion 2030-11-08
- Results posted
- Not yet
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
From ClinicalTrials.gov, last updated 2026-09-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $281,120 in research payments for this study in 2025 (7 payments).
Products named: Bimzelx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Navid Ezra, M.D. Dermatology · Thousand Oaks, CA
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Howard L. Sofen, M.D. Dermatology · Los Angeles, CA
- Scott A. Fretzin, M.D. Dermatology · Indianapolis, IN
- Lara Wine Lee, M.D. Dermatology · Charleston, SC
- William Abramovits, M.D. Dermatology · Dallas, TX
- Angela Y. Moore, MD, PA Dermatopathology · Arlington, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- First Oc Dermatology Research Inc $82,302
- Dermatology Research Associates Inc $70,405
- Dawes Fretzin Clinical Research $46,191
- Medical Univ. of S. Carolina $32,690
- Arlington Research Center Inc $26,770
- Northridge Clinical Trials $19,653
- Reveal Research Institute PLLC $3,109
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.